MindMed Corporate Presentation August 2024

MindMed is a neuro-pharmaceutical company developing psychedelic-inspired medicines, with lead candidates MM120 (lysergide D-tartrate) and MM402 (R(-)-MDMA) targeting brain health conditions. The company has a diversified clinical pipeline, substantial cash runway through 2027, and experienced management focused on regulatory approval and market protection strategies.